Corrigendum: Table and Text Correction. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians

Article information

Diabetes Metab J. 2018;42(2):177-177

Publication date (electronic) : 2018 April 19

doi : https://doi.org/10.4093/dmj.2018.42.2.177

Ahmed Iqbal ¹^,²^,³^,^*, Peter Novodvorsky ¹^,²^,^*, Simon R. Heller ¹^,²

¹Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

²Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

³Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

*Ahmed Iqbal and Peter Novodvorsky contributed equally to this study as first authors.

Diabetes Metab J 2018;42:3-18. https://doi.org/10.4093/dmj.2018.42.1.3

We have three errors in ‘Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians,’ these are as follows:

In Table 1, the manufacturer of insulin degludec (Tresiba) was wrongly listed as Sanofi. This should be NovoNordisk.
In the subsection ‘INSULIN PREPARATIONS AND ADMINISTRATION,’ on page 6, insulin degludec (Tresiba) was mentioned, but without manufacturer, this should be NovoNordisk.
In the subsection ‘USE OF METFORMIN IN T1DM,’ page 7, the original text ‘reduction of progression of caroT1DM artery intima-media thickness,’ should be corrected to ‘reduction of progression of carotid artery intima-media thickness.’

We apologize for any inconvenience that this may have caused.

Article information Continued

Korean Diabetes Association

(open-access, http://creativecommons.org/licenses/by-nc/4.0/) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.